|
|
|
| Methylation of SOX17 Gene in Plasma Circulating DNA and Its Correlation with Disease Status and Prognosis in Patients with Papillary Thyroid Carcinoma |
| CHAO Xiangsong, SUN Jiabin, HOU Yinglong |
| Jiamusi Central Hospital, Heilongjiang Jiamusi 154002, China |
|
|
|
|
Abstract Objective: To explore the relationship between SOX17 gene methylation in plasma circulating DNA and the disease condition and prognosis of patients with papillary thyroid carcinoma (PTC). Methods: Thyroid cancer tissue and preoperative blood samples were collected from 152 PTC patients who underwent surgical resection between June 2022 and December 2023. Methylation-specific PCR (MSP) was used to detect SOX17 promoter methylation in PTC tissues and plasma circulating DNA. Results: MSP results showed that 71 out of 152 PTC tissue samples (46.7%) and 76 plasma circulating DNA samples (50.0%) exhibited SOX17 methylation. Spearman correlation analysis indicated a significant correlation between SOX17 methylation in plasma circulating DNA and PTC tissues (r=0.382, P<0.001). SOX17 methylation in PTC tissue and plasma circulating DNA was significantly associated with tumor stages Ⅱ~Ⅲ, tumor size ≥2cm, and lymph node metastasis (LNM) (P<0.05). Furthermore, SOX17 methylation in plasma circulating DNA was significantly related to the occurrence of extrathyroidal extension (ETE) (P<0.05). SOX17 methylation in plasma circulating DNA was identified as an independent factor influencing LNM and ETE in PTC patients (OR=9.564, 2.744; 95% CI=3.875~23.602, 1.109~6.792, P<0.05). The predictive ability of SOX17 methylation in plasma circulating DNA for LNM and ETE was relatively high, with an area under the curve (AUC) of 0.731 and 0.630 (sensitivity 74.0%, 65.6%; specificity 72.2%, 60.4%). In contrast, the predictive ability of SOX17 methylation in PTC tissues for LNM and ETE was lower, with an AUC of 0.604 and 0.562 (sensitivity 57.5%, 54.1%; specificity 63.3%, 58.2%). Conclusion: SOX17 promoter methylation in tumor tissue and plasma DNA exhibits high consistency during the occurrence and progression of PTC. Moreover, SOX17 promoter methylation in plasma DNA has a higher predictive value for LNM and ETE.
|
|
|
|
|
|
[1] Amanullah M,Pan M,Lu K,et al.Tumor-infiltrating immune cell landscapes in the lymph node metastasis of papillary thyroid cancer[J].Curr Oncol,2023,30(3): 2625-2641.
[2] Song B,Lin Z,Feng C,et al.Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis[J].Front Endocrinol,2023(14): 1252389.
[3] Hu H,Ho D H H,Tan D S,et al.Evaluation of the determinants for improved pluripotency induction and maintenance by engineered SOX17[J].Nucleic Acids Res,2023,51(17): 8934-8956.
[4] Goto N,Westcott P M K,Goto S,et al.SOX17 enables immune evasion of early colorectal adenomas and cancers[J].Nature,2024,627(8004): 636-645.
[5] Connal S,Cameron J M,Sala A,et al.Liquid biopsies: the future of cancer early detection[J].Transl Med,2023,21(1): 118.
[6] Lianidou E.Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook[J].Mol Oncol,2021,15(6): 1683-1700.
[7] Vitale I,Shema E,Loi S,et al.Intratumoral heterogeneity in cancer progression and response to immunotherapy[J].Nat Med,2021,27(2): 212-224.
[8] Ming X,Duppee J L,Gallo V,et al.SOX17 promotes oligodendrocyte regeneration by dual modulation of hedgehog and Wnt signaling[J].Iscience,2020,23(10): 101592.
[9] Zhang W,Ruan X,Li Y,et al.KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway[J].Theranostics,2022,12(4): 1500.
[10] Sheikholeslami S,Zarif-yeganeh M,Farashi S,et al.Promoter methylation of tumor suppressors in thyroid carcinoma: a systematic review[J].Iran Public Health,2021,50(12): 2461-2472. |
|
|
|
2024, Vol. 30 
